Keywords: BioMarin, Huxley Pharma, M&A, LEMS, Autoimmune disease

BioMarin buys Huxley Pharma for $15 million plus up to conditional $43.5 million

Article | 27 October 2009

BioMarin Pharmaceutical says that it has acquired fellow USA-based Huxley Pharmaceuticals, which has rights to a proprietary form of 3,4-diaminopyridine (3,4 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in